07.06.2024 17:13:35

Advanced R&D capabilities and proven efficacy of our unique fast pain-relief mouth ulcer cream

bonyf NV / Key word(s): Research Update/Scientific publication
Advanced R&D capabilities and proven efficacy of our unique fast pain-relief mouth ulcer cream

07-Jun-2024 / 17:13 CET/CEST


Advanced R&D capabilities and proven efficacy of our unique fast pain-relief mouth ulcer cream

fncls.ssp?fn=download2_file&code_str=f12d018856f9a1314a3c0a9a1ceff13f

Ghent (Belgium), June 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production and marketing of oral, denture, orthodontic and wound care products, is proud to reaffirm our commitment to R&D, as well as to highlight the proven effectiveness of our unique fast pain-relief mouth ulcer cream AphtoFix®. Our dedication to advancing oral healthcare through cutting-edge research and clinical studies sets us apart as a premier provider of effective solutions.

As a company deeply invested in R&D, we continuously strive to develop innovative products that meet the highest standards of efficacy and safety. Our mouth ulcer cream is a testament to this commitment, formulated with a proprietary blend of clinically proven ingredients that deliver comprehensive relief and promote rapid healing.

A recent clinical study1, conducted by our esteemed team of researchers, underscores the efficacy of our mouth ulcer cream. The study, published in the Journal of Dental Hygiene Science, reveals the following key findings:

 Rapid Pain Relief: Significant pain reduction from day 1

 Accelerated Healing: A faster healing rate of the lesion with an average of 7 days

 Protective Barrier: Due to its muco-adhesive property, AphtoFix® in contact with saliva acts as an elastic, thin and durable protective barrier against the oral environment, thus favoring prompt healing by means of isolating the ulcer from food debris and bacteria.

These results validate our product's unique formulation. The clinical study concluded that our mouth ulcer cream offers a superior solution for those seeking rapid relief and effective healing.

"Our mission at bonyf is to advance healthcare through innovation and rigorous research," said Jean-Pierre Bogaert, CEO of bonyf. "This study highlights the exceptional efficacy of our mouth ulcer cream and showcases our capability as a leading R&D company. We are dedicated to providing solutions that enhance the quality of life for individuals worldwide."

bonyf's mouth ulcer cream is readily available for purchase and through leading retailers in different countries. For more information about our product, its benefits, and our ongoing research initiatives, please visit www.bonyf.com or contact us via the Contact Form.

About bonyf is at the forefront of oral healthcare innovation, with a robust focus on research and development. Our commitment to advancing health and well-being through cutting-edge solutions ensures that we provide products of the highest quality and efficacy.

1 Simone Marconcini, Enrica Giammarinaro, Giacomo Oldoini, and Annamaria Genovesi. (2023). Assessment of the Effectiveness of a Film-Forming Cream in the Management of Oral Aphthous Ulcers: A Placebo-Controlled Randomized Clinical Trial. J Dent Hyg Sci. 23:88-92. Published online at: https://doi.org/10.17135/jdhs.2023.23.2.88

bonyf’s strengths

  • Products with patented formulations
  • Produced in Switzerland compliant with stringent international quality regulations
  • Proven clinical efficacy
  • Commercial presence in 37 countries
  • Prospects for solid growth and rapid profitability
  • A fast-growing oral and dental care market


fncls.ssp?fn=download2_file&code_str=c79fae7ffede7d0ca1903ec04b2ab2ce

 

About bonyf

Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market.

For more information about bonyf and its innovative oral care products, please visit www.bonyf.com.

 

bonyf

Jean-Pierre Bogaert

investor@bonyf.com
fncls.ssp?fn=download2_file&code_str=fc61bcc3187a54e7e553fb4f1fed6603

 



Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: bonyf NV
Doornzelestraat 114 D
9000 Gent
Belgium
Phone: +41 79 412 42 79
E-mail: president@bonyf.com
Internet: www.bonyf.com
ISIN: BE6333353298
EQS News ID: 1920941

 
End of Announcement - EQS News Service

1920941  07-Jun-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1920941&application_name=news&site_id=smarthouse

Analysen zu bonyfmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

bonyf 18,10 0,00% bonyf